…
Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -76.95M | -72.52M | -133.62M | -168.68M | -32.29M |
| Net income | -77.06M | -72.49M | -133.70M | -168.72M | -32.41M |
| Selling general administrative | 39.23M | 43.88M | 67.78M | 83.47M | 85.72M |
| Selling and marketing expenses | 45.88M | 41.57M | 39.07M | 59.89M | 49.60M |
| Gross profit | 45.73M | 48.83M | 16.86M | 39.46M | 17.05M |
| Reconciled depreciation | 8.08M | 10.34M | 10.57M | 5.93M | 2.09M |
| Ebit | -75.46M | -71.26M | -133.62M | -193.02M | -192.73M |
| Ebitda | -67.38M | -60.92M | -123.04M | -183.60M | -190.64M |
| Depreciation and amortization | 8.08M | 10.34M | 10.57M | 9.42M | 2.09M |
| Non operating income net other | - | - | - | 24.34M | 161.09M |
| Operating income | -86.42M | -74.41M | -145.61M | -193.02M | -192.73M |
| Other operating expenses | 184.03M | 156.47M | 211.51M | 266.41M | 255.29M |
| Interest expense | 1.49M | 1.26M | 0.00M | 0.00M | 0.65M |
| Tax provision | 0.11M | -0.03M | 0.08M | 0.04M | 0.12M |
| Interest income | 5.91M | 5.02M | 7.45M | 3.38M | 2.57M |
| Net interest income | 4.42M | 3.76M | 7.45M | 3.38M | 1.92M |
| Income tax expense | 0.11M | -0.03M | 0.08M | 0.04M | 0.12M |
| Total revenue | 97.61M | 82.06M | 65.90M | 73.39M | 62.56M |
| Total operating expenses | 132.15M | 123.24M | 162.47M | 232.48M | 209.78M |
| Cost of revenue | 51.88M | 33.23M | 49.04M | 33.93M | 45.51M |
| Total other income expense net | 9.46M | 1.89M | 11.99M | 24.34M | 160.44M |
| Net income from continuing ops | -77.06M | -72.49M | -133.70M | -168.72M | -32.41M |
| Net income applicable to common shares | - | - | - | -168.72M | -32.41M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 296.53M | 256.08M | 304.27M | 417.57M | 571.97M |
| Intangible assets | 7.52M | 8.92M | 10.32M | - | - |
| Other current assets | 10.48M | 12.26M | 10.39M | 9.49M | 40.88M |
| Total liab | 100.55M | 87.25M | 84.22M | 92.21M | 124.27M |
| Total stockholder equity | 195.98M | 168.83M | 220.05M | 325.36M | 447.69M |
| Other current liab | 30.09M | 23.03M | 20.17M | 26.34M | 29.57M |
| Common stock | 0.03M | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.03M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -879.19M | -802.13M | -729.64M | -595.94M | -427.21M |
| Other liab | - | - | - | 10.91M | 46.76M |
| Other assets | - | - | - | 7.54M | 21.27M |
| Cash | 150.49M | 88.78M | 134.44M | 162.56M | 422.84M |
| Total current liabilities | 65.12M | 48.22M | 44.27M | 51.33M | 49.83M |
| Current deferred revenue | 26.91M | 16.14M | 15.62M | 15.86M | 13.07M |
| Net debt | -130.09M | -65.94M | -109.41M | -130.67M | -395.15M |
| Short term debt | 2.68M | 2.44M | 2.19M | 1.93M | 1.39M |
| Short long term debt total | 20.40M | 22.84M | 25.03M | 31.89M | 27.69M |
| Other stockholder equity | 1075.15M | 970.94M | 949.67M | 921.28M | 874.89M |
| Property plant equipment | - | - | - | 31.33M | 38.79M |
| Total current assets | 249.10M | 192.61M | 231.26M | 357.14M | 511.90M |
| Net tangible assets | - | - | - | 325.36M | 447.69M |
| Short term investments | - | - | 0.00M | 75.25M | - |
| Net receivables | 26.74M | 20.79M | 13.42M | 14.69M | 11.94M |
| Inventory | 61.39M | 70.79M | 73.02M | 59.97M | 36.24M |
| Accounts payable | 5.44M | 4.25M | 5.09M | 7.21M | 5.80M |
| Accumulated other comprehensive income | - | - | 0.00M | - | -571.97M |
| Common stock total equity | - | - | - | 0.02M | 0.02M |
| Retained earnings total equity | - | - | - | -595.94M | -427.21M |
| Non currrent assets other | 6.66M | 16.79M | 21.70M | 7.54M | 21.27M |
| Non current assets total | 47.43M | 63.47M | 73.01M | 60.43M | 60.06M |
| Capital lease obligations | 20.40M | 22.84M | 25.03M | 29.97M | 29.08M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -2.66M | 70.41M | -93.78M | -1.99M |
| Change to liabilities | - | - | - | 4.38M | -3.21M |
| Total cashflows from investing activities | -3.35M | -2.66M | 70.41M | -93.78M | -9.87M |
| Net borrowings | - | - | 0.00M | - | -4.37M |
| Total cash from financing activities | 77.76M | -1.50M | 0.23M | 2.88M | 565.69M |
| Change to operating activities | - | - | - | -5.31M | -30.43M |
| Net income | -77.06M | -72.49M | -133.70M | -168.72M | -32.41M |
| Change in cash | 61.71M | -45.86M | -28.18M | -260.01M | 366.63M |
| Begin period cash flow | 92.79M | 138.65M | 166.83M | 426.84M | 60.21M |
| End period cash flow | 154.50M | 92.79M | 138.65M | 166.83M | 426.84M |
| Total cash from operating activities | -12.70M | -41.71M | -98.82M | -169.12M | -189.19M |
| Issuance of capital stock | 81.01M | 0.00M | 0.00M | 0.00M | 548.40M |
| Depreciation | 8.08M | 10.34M | 10.57M | 5.93M | 2.09M |
| Other cashflows from investing activities | - | 0.04M | 0.01M | 0.06M | - |
| Change to inventory | 1.43M | 2.22M | -34.13M | -24.51M | -11.29M |
| Change to account receivables | -6.75M | -8.50M | -0.16M | -3.06M | -6.13M |
| Sale purchase of stock | - | - | - | 2.98M | 21.71M |
| Other cashflows from financing activities | 75.53M | -1.50M | 0.23M | -0.10M | 21.66M |
| Change to netincome | - | - | - | 23.07M | -107.82M |
| Capital expenditures | 3.35M | 2.69M | 5.78M | 18.30M | 7.88M |
| Change receivables | - | - | - | -3.06M | -6.13M |
| Cash flows other operating | - | - | - | -6.21M | -32.15M |
| Cash and cash equivalents changes | - | - | - | -260.01M | 366.63M |
| Change in working capital | 15.23M | -4.82M | -20.13M | -29.40M | -51.05M |
| Stock based compensation | 23.43M | 21.03M | 27.48M | 42.53M | 47.80M |
| Other non cash items | 17.61M | 4.23M | 16.96M | -19.46M | 2.29M |
| Free cash flow | -16.05M | -44.40M | -104.60M | -187.42M | -197.06M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BFLY Butterfly Network Inc |
0.21 3.30% |
6.58 | - | - | 18.52 | 10.42 | 16.65 | -9.57 |
| ABT Abbott Laboratories |
-0.36 0.33% |
109.56 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.14 0.14% |
101.66 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-0.84 0.26% |
325.03 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
0.56 1.12% |
50.41 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.
1600 District Avenue, Burlington, MA, United States, 01803
781 557 4800
220
| Name | Title | Year Born |
|---|---|---|
| Dr. Jonathan M. Rothberg Ph.D. | Founder, Interim CEO & Chairman | 1964 |
| Dr. Andrei G. Stoica Ph.D. | Chief Technology Officer | 1973 |
| Mr. Darius Shahida | Chief Strategy Officer & Chief Bus. Devel. Officer | 1992 |
| Dr. Todd M. Fruchterman M.D., Ph.D. | Exec. Officer | 1970 |
| Ms. Heather C. Getz CPA, M.B.A. | Exec. VP & CFO | 1975 |
| Mr. David H. Ramsey | Chief Information Officer | 1970 |
| Mr. Larry Weiss | Chief Legal Officer & Corp. Sec. | NA |
| Ms. Tamara Dillon | Chief People Officer | NA |
| Dr. John Martin F.A.C.S., M.B.A., M.D. | Chief Medical Officer | 1959 |
| Mr. Troy Quander | Sr. VP of Regulatory & Quality | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.